On September 11, 2019 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, reported the pricing of the sale of 4,000,000 shares of common stock of OncoCyte Corporation at a price to buyers of $1.66 per share, the closing price as of September 10, 2019 (Press release, Lineage Cell Therapeutics, SEP 11, 2019, View Source [SID1234539433]). Gross proceeds from the sale were $6.6 million, before payment of $100,000 in sales commissions and offering expenses. The sale is expected to close on September 13, 2019, subject to customary closing conditions. Following the completion of the sale, Lineage will own approximately 16% or 8.4 million shares of OncoCyte’s outstanding common stock. Based on the closing price of OncoCyte’s common stock on September 10, 2019, the value of Lineage’s remaining OncoCyte shares following the closing is approximately $14.0 million. Lineage has agreed not to sell additional shares of OncoCyte common stock until January 1, 2020 or unless the OncoCyte common stock price is above $3.00.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our objective is to build Lineage into a premier cell therapy company. This latest transaction involving the sale of OncoCyte shares is part of a larger strategy to raise operating capital from time to time to support our three clinical-stage programs through sources other than Lineage common stock," stated Brian M. Culley, Chief Executive Officer. "We have no plans to conduct additional sales of OncoCyte in the near-term. We continue to have other funding mechanisms at our disposal via our remaining investments in AgeX Therapeutics, Inc. and Hadasit Bio-Holdings Ltd., as well as a $21.6 million promissory note due to us in August 2020 from Juvenescence Ltd. In parallel, we continue to assess other funding and strategic alliance opportunities which may be available through our existing or future potential partners. While it is imperative to support our internal programs, we remain one of OncoCyte’s largest shareholders and are highly supportive of their short and long-term growth plans. We look forward to their continued progress toward becoming a comprehensive diagnostic content company serving the needs of lung cancer patients across disease stages."

The Special Equities Group, LLC a division of Bradley Woods & Co. Ltd. acted as exclusive placement agent with respect to part of this transaction.

On September 11, 2019 C4 Imaging LLC is reported the first prostate cancer treatment utilizing Orion, a novel medical device that’s designed to facilitate the use of MRI in improving the accuracy of treatment (Press release, C4 IMAGING, SEP 11, 2019, View Source [SID1234539450]). The procedure was performed by Dr Peter Rossi at the Calaway Young Cancer Center in Glenwood Springs, Colorado.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are thrilled to be first to use Orion HDR MRI Markers in the treatment of a prostate cancer patient," said Peter Rossi MD. "This kind of state-of-the-art care benefits our patients by supporting a treatment plan that is tailored to their individual anatomy. Effective treatment that minimizes the possibility of side effects is key as we approach the care of our patients. We are proud to be a leader in adopting this kind of advanced treatment," Dr. Rossi added.

High Dose Rate (HDR) brachytherapy is a form of radiotherapy and a standard option for the curative treatment of many forms of cancer. It involves temporarily placing an applicator into the patient and then using medical imaging to identify the location in relation to the cancer and surrounding healthy tissue. A radioactive source is placed inside the applicator and irradiates the cancer before being removed. The popularity of HDR has increased in recent years due to its effectiveness and convenience.

The precise positioning of HDR applicators prior to treatment is critical for accurate delivery of therapy. Currently, this placement is usually guided by computed tomography (CT) imaging of metal wires that are temporarily placed inside the applicator. MRI can provide more anatomical detail than CT. The Orion HDR Marker creates a well-defined, positive MRI signal and allows the superior anatomical imaging properties of MRI to be effectively utilized when planning treatment, offering the potential for effective treatment that minimizes the possibility of side effects.

Andrew Bright, President and CEO of C4 Imaging commented, "We’re excited that Dr. Rossi, a nationally recognized leader in brachytherapy, has chosen to adopt Orion to further improve on his ability to provide highly personalized patient care. The Calaway Young Cancer Center exemplifies how cutting-edge technology can be delivered at a regional center of excellence." He added, "We’d also like to acknowledge our commercial partner Theragenics, who, as a longtime leader in serving the brachytherapy community, were instrumental in introducing Dr Rossi and his team to the benefits of Orion."

On September 11, 2019 Biogen Inc. (Nasdaq:BIIB) reported it will report third quarter 2019 financial results Tuesday, October 22, 2019, before the financial markets open (Press release, Biogen, SEP 11, 2019, View Source [SID1234539468]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following the release of the financials, the Company will host a live webcast with Biogen management from 8:00-9:00 am ET. To access the live webcast, please go to the investors section of Biogen’s website at View Source Following the live webcast, an archived version of the call will be available on the website.

On September 11, 2019 Q BioMed, Inc. (OTCQB: QBIO) and Chemveda Life Sciences are very pleased to announce that after the recent successful chemical synthesis of a unique natural compound that has shown remarkable efficacy as a potential chemotherapy for the treatment of liver cancer, the two companies have formalized a collaboration to continue the work and to scale-up manufacturing of cGMP product for planned pre-clinical testing and clinical trials (Press release, Q BioMed, SEP 11, 2019, View Source [SID1234539451]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Since February 2017, Q BioMed and Chemveda have been engaged in a joint research program to synthesize uttroside B and several other derivatives. The goal of the program is to study their potential use in clinical trials for the treatment of hepatocellular carcinoma (liver cancer) as well as other cancers. The original compound was isolated and characterized from the leaves of Solanum nigrum Linn, a plant widely used in traditional medicines.

In a Scientific Reports study, researchers showed that in animal models, uttroside B was ten times more cytotoxic to the HepG2 liver cancer cell line than sorafenib, the only drug approved by the Food and Drug Administration for liver cancer at the time and the current first line treatment for hepatocellular carcinoma. Uttroside B drastically reduced tumors in mice bearing human liver cancer xenografts. In addition, in pre-clinical experiments, uttroside B induced cytotoxicity in all liver cancer cell lines and researchers were able to confirm its biological safety, both by in vitro and in vivo studies. Q BioMed is awaiting confirmatory cell line efficacy data from the synthesized drug product and its derivatives.

Denis Corin, Q BioMed CEO said, "Chemveda has been an excellent partner in this program, both in terms of execution and problem solving, and we look forward to the next phase as we advance this promising molecule and others towards the clinic."

Bheema Paraselli, Chemveda’s President & CEO said, "Since its inception in early 2017 we have been very interested in this research given to the novelty of its clinical end-point & nobility of this approach. What helped us cut through the initial uncertainty and risks surrounding the milestone approach was our stringent due-diligence, attention to detail, and tailored scientific approach. We are very thankful to Q BioMed for being of tremendous help."

Under the Agreement and depending upon reaching certain milestones, Q BioMed have agreed to pay Chemveda a combination of cash and stock and capped royalty on net sales of any and all drug product(s) resulting from the collaboration. Subject to the terms of the Agreement, Chemveda shall have the first right of refusal and, if exercised, the exclusive right to manufacture any products developed as a result of the program for pre-commercial and commercial production.

Chemotherapeutic options for liver cancer are limited, and the prognosis of patients remains challenging. According to the Centers for Disease Control and Prevention, it is the second most common cause of cancer deaths worldwide, claiming approximately 750,000 lives each year. In the US, the American Cancer Society estimates that 42,000 people will be diagnosed with liver cancer in 2019 and that 32,000 will die from the disease this year. Liver cancer incidence has more than tripled since 1980 and deaths in the US have increased 56% since 2003.

The uttroside B technology is covered by a provisional patent application. To see the full Scientific Reports study, go to:View Source

Please visit www.QBioMed.com for more information on our various pipeline products.

On September 11, 2019 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, reported that clinical data on its investigational anti-PD-1 antibody tislelizumab, its investigational BTK inhibitor zanubrutinib, and its investigational PARP inhibitor pamiparib, will be presented in seven oral presentations and four poster presentations at the 22nd Annual Meeting of the Chinese Society of Clinical Oncology (CSCO), taking place September 18-22, 2019 in Xiamen, China (Press release, BeiGene, SEP 11, 2019, View Source [SID1234539469]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oral Presentations:

Title: Tislelizumab in Chinese Patients with Non-Small Cell Lung
Cancer (NSCLC) and Nasopharyngeal Carcinoma (NPC)
Session: Lung Cancer Session 1
Date: Thursday, September 19
Time: 11:20 – 11:25
Location Auditorium, Level 1
Presenter Qing Zhou, M.D., Ph.D., Guangdong Provincial People’s Hospital

Title: Tislelizumab for Relapsed/Refractory Classical Hodgkin
Lymphoma: Updated Follow-up Efficacy and Safety Results
from a Phase 2 Study
Session: Innovative Drug Clinical Data Session 1
Date: Thursday, September 19
Time: 14:30 – 14:40
Location Strait Hall, Level 2
Presenter: Yuqin Song, M.D., Ph.D., Beijing Cancer Hospital

Title: Tislelizumab in Chinese Patients with Melanoma, Urothelial
Carcinoma (UC), and Renal Cell Carcinoma (RCC)
Session: Kidney Cancer Session 4
Date: Thursday, September 19
Time: 16:35 – 16:40
Location Conference Room 2A, Level 2
Presenter: Lili Mao, M.D., Ph.D. Beijing Cancer Hospital

Title: Tislelizumab in Chinese Patients with Esophageal Cancer
(EC), Gastric Cancer (GC), Hepatocellular Carcinoma (HCC),
and Microsatellite Instability-High/Mismatch Repair Deficient
(MSI-H/dMMR) Tumors
Session: Advanced Gastric Cancer Session 3
Date: Friday, September 20
Time: 11:24 – 11:36
Location Banquet Hall 1, Level 2
Presenter: Lin Shen, M.D., Ph.D., Beijing Cancer Hospital

Title: Safety and Efficacy in Patients with Long-Term Exposure
(LTE) to Tislelizumab, an Investigational Anti-PD-1 Antibody,
in a First-in-Human Phase 1 Study
Session: Immuno-Oncology Session 3
Date: Friday, September 20
Time: 11:54 – 12:00
Location Hall 1G, Level 1
Presenter Chia-Jui Yen, M.D., Ph.D., National Cheng Kung University Hospital

Title: Tislelizumab Plus Chemotherapy as First-Line Treatment for
Chinese Patients with Lung Cancer
Session: Lung Cancer Session 3
Date: Saturday, September 21
Time: 11:38 – 11:44
Location Auditorium, Level 1
Presenter: Zhijie Wang, M.D., Ph.D., Cancer Hospital, Chinese Academy of Medical Sciences

Title: Tislelizumab in Combination with Chemotherapy as
Treatment for Chinese Patients with Esophageal Squamous
Cell Carcinoma (ESCC)
Session: Innovative Drug Clinical Data Session 1
Date: Saturday, September 21
Time: 14:30 – 14:40
Location Banquet Hall 2, Level 2
Presenter: Ru Jia, M.D., The Fifth Medical Center, General Hospital of the People’s Liberation Army

Poster Presentations:

Title: Dose Escalation of Pamiparib in Chinese Patients with High-
Grade Non-Mucinous Ovarian Cancer (HGOC) or Advanced
Triple-Negative Breast Cancer (TNBC)
Board #: P-36
Date: Thursday, September 19
Time: Afternoon
Location: Strait Hall Poster Area, Level 2
Presenter: Xiyan Mu, M.D., BeiGene

Title: Zanubrutinib for Patients with Relapsed or Refractory
Chronic Lymphocytic Leukemia or Small Lymphocytic
Lymphoma
Board #: P-45
Date: Friday, September 20
Time: Morning
Location: Strait Hall Poster Area, Level 2
Presenter: Meng Ji, M.D., BeiGene

Title: Zanubrutinib, a Highly Specific BTK Inhibitor in Chinese
Patients with Relapsed/Refractory B-cell Malignancies:
Follow-up Report of a Phase 1 Trial in China
Board #: P-46
Date: Friday, September 20
Time: Morning
Location: Strait Hall Poster Area, Level 2
Presenter: Chenmu Du, M.D., BeiGene

Title: The molecular binding mechanism of tislelizumab, an
investigational anti-PD-1 antibody, is differentiated from
pembrolizumab and nivolumab
Board #: P-60
Date: Friday, September 20
Time: Morning
Location: Strait Hall Poster Area, Level 2
Presenter: Ye Liu, Ph.D., BeiGene